Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Precio Actual
Capitalización
Desviación
Crec. Y/Y
Margen EBIT
ROIC
PEG Ratio
ROE
Crec. EPS 3A
Net Debt / EBITDA
Último Análisis
Proyecciones CAGR
Proyecciones de tasa de crecimiento anual compuesta basadas en diferentes modelos de valoración. CAGR EV/FCF es la métrica principal.
Múltiplos de Valoración
Múltiplos de valoración utilizados para las estimaciones de CAGR y precios objetivo.
Gráfico de Evolución del Precio
Precios Objetivo FCF
Precios futuros estimados de la acción basados en proyecciones de flujo de caja libre.
Calculadora de Sensibilidad
Compara el CAGR de tu valoración con el que resultaría al aplicar diferentes múltiplos (LTM y Fair P/E).
Reverse DCF
Rentabilidad mínima que exiges a tu inversión. Refleja el coste de oportunidad y el riesgo.
Múltiplo EV/FCF al que se valorará la empresa al final del periodo de proyección.
Notas
Rendimiento Histórico vs. Índices
Rendimiento anual (YTD) de la acción comparado con índices y materias primas de referencia.
| statistics.year | Rendimiento VRTX | Rendimiento Bitcoin | Rendimiento vs. Bitcoin | Rendimiento Gold | Rendimiento vs. Gold | Rendimiento Bono USA 7-10y | Rendimiento vs. Bono USA 7-10y | Rendimiento Bono USA 1-3y | Rendimiento vs. Bono USA 1-3y | Rendimiento Bono USA 20+y | Rendimiento vs. Bono USA 20+y | Rendimiento Dow Jones | Rendimiento vs. Dow Jones | Rendimiento S&P 500 | Rendimiento vs. S&P 500 | Rendimiento NASDAQ 100 | Rendimiento vs. NASDAQ 100 | Rendimiento MSCI World | Rendimiento vs. MSCI World | Rendimiento Russell 2000 | Rendimiento vs. Russell 2000 | Rendimiento STOXX Europe 600 | Rendimiento vs. STOXX Europe 600 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026 YTD en Vivo | -5.28% | -10.01% | +4.73% | 8.78% | -14.06% | -0.54% | -4.74% | -0.35% | -4.93% | -0.37% | -4.91% | 1.75% | -7.03% | 4.47% | -9.75% | 6.89% | -12.17% | 4.70% | -9.97% | 11.11% | -16.39% | 2.43% | -7.71% |
2025 | 11.73% | 110.77% | -99.04% | 26.96% | -15.22% | -3.73% | +15.46% | 0.05% | +11.68% | -11.17% | +22.90% | 12.80% | -1.07% | 24.01% | -12.28% | 30.78% | -19.05% | 17.88% | -6.15% | 10.80% | +0.93% | 5.50% | +6.23% |
2024 | -2.00% | 153.66% | -155.66% | 11.76% | -13.75% | -0.15% | -1.85% | 0.98% | -2.98% | -2.54% | +0.54% | 13.74% | -15.74% | 24.73% | -26.73% | 44.52% | -46.52% | 21.92% | -23.92% | 15.78% | -17.78% | 11.67% | -13.67% |
2023 | 42.26% | -65.23% | +107.48% | 0.78% | +41.48% | -15.93% | +58.19% | -5.00% | +47.26% | -31.00% | +73.26% | -9.40% | +51.66% | -19.95% | +62.21% | -33.89% | +76.15% | -19.70% | +61.96% | -22.50% | +64.76% | -13.29% | +55.55% |
2022 | 29.77% | 60.33% | -30.56% | -6.24% | +36.01% | -4.15% | +33.92% | -0.98% | +30.76% | -5.94% | +35.71% | 20.23% | +9.54% | 28.79% | +0.98% | 23.20% | +6.57% | 21.22% | +8.55% | 15.39% | +14.39% | 21.66% | +8.11% |
2021 | -4.28% | 301.93% | -306.21% | 23.90% | -28.19% | 8.33% | -12.61% | 2.02% | -6.30% | 15.12% | -19.41% | 6.02% | -10.30% | 15.29% | -19.58% | 41.75% | -46.04% | 12.94% | -17.23% | 18.48% | -22.77% | -4.64% | +0.35% |
2020 | 7.70% | 88.85% | -81.16% | 17.78% | -10.08% | 5.55% | +2.14% | 1.20% | +6.50% | 10.91% | -3.22% | 21.91% | -14.22% | 28.34% | -20.64% | 34.60% | -26.91% | 25.23% | -17.53% | 23.05% | -15.36% | 23.42% | -15.72% |
2019 | 33.44% | -71.79% | +105.23% | -3.12% | +36.56% | -0.97% | +34.41% | -0.24% | +33.68% | -3.17% | +36.61% | -6.03% | +39.47% | -7.01% | +40.45% | -5.30% | +38.74% | -11.16% | +44.60% | -13.00% | +46.44% | -13.42% | +46.86% |
2018 | 8.37% | 1,184.56% | -1,176.19% | 11.93% | -3.56% | 0.76% | +7.61% | -0.63% | +9.00% | 6.03% | +2.34% | 24.33% | -15.96% | 18.42% | -10.04% | 27.16% | -18.78% | 19.45% | -11.08% | 12.45% | -4.08% | 7.16% | +1.21% |
2017 | 100.11% | 1,184.56% | -1,084.45% | 11.93% | +88.18% | -1.15% | +101.26% | -0.02% | +100.13% | -1.91% | +102.02% | 24.33% | +75.78% | 18.42% | +81.69% | 27.16% | +72.95% | 19.45% | +80.65% | 12.45% | +87.66% | 7.16% | +92.95% |
| common.average | 22.18% | 293.76% | -271.58% | 10.45% | +11.74% | -1.20% | +23.38% | -0.30% | +22.48% | -2.40% | +24.58% | 10.97% | +11.21% | 13.55% | +8.63% | 19.69% | +2.50% | 11.19% | +10.99% | 8.40% | +13.78% | 4.77% | +17.42% |
Historial de Valoración
Registro de los cambios en los parámetros de valoración a lo largo del tiempo.
Fecha de Valoración | Crec. Y/Y | Margen EBIT | Deuda/Pat. | PER | EV/FCF | CAGR EV/EBITDA | CAGR EV/EBIT | Objetivo 2025 | Objetivo 2026 | Objetivo 2027 | Objetivo 2028 | Objetivo 2029 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9/29/2025 | 8.7% | 46.7% | -1.3x | 25x(26x) | 25x | 20x | 20x | $437.87 | $500.43 | $555.80 | $602.68 | $653.51 |
Historial de Dividendos
Evolución de los dividendos por acción y métricas de crecimiento.